Phase II evaluation of topotecan for pediatric central nervous system tumors

✍ Scribed by Susan M. Blaney; Peter C. Phillips; Roger J. Packer; Richard L. Heideman; Stacey L. Berg; Peter C. Adamson; Jeffrey C. Allen; Stephen E. Sallan; Regina I. Jakacki; Beverly J. Lange; Gregory H. Reaman; Marc E. Horowitz; David G. Poplack; Frank M. Balis

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 473 KB
• Volume: 78
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19960801)78:3<527::aid-cncr21>3.0.co;2-#

✦ Synopsis

BACKGROUND.

Topotecan is a topoisomerase I inhibitor that has good penetration across the blood-brain barrier and significant antitumor activity against human brain tumor xenografts. In a Phase I trial in children with refractory cancer, topotecan was well tolerated when administered as a 24-hour infusion. The maximum tolerated dose was 5.5 mg/m' and the dose-limiting toxicity was myelosuppression.